Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.

B7-H1 Antigen / genetics Biomarkers, Tumor / genetics Gene Expression Regulation, Neoplastic Humans Lymphocytes, Tumor-Infiltrating / immunology Macrophages / immunology Male Mutation Neoplasm Grading Neoplasm Staging Oncogene Fusion Prostatic Neoplasms / genetics RNA-Seq / methods

Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
07 2020
Historique:
received: 24 07 2019
revised: 01 11 2019
accepted: 17 04 2020
pubmed: 24 4 2020
medline: 16 1 2021
entrez: 24 4 2020
Statut: ppublish

Résumé

Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as

Identifiants

DOI: 10.1158/2326-6066.CIR-19-0568 PMID: 32321776
pubmed: 32321776
pii: 2326-6066.CIR-19-0568
doi: 10.1158/2326-6066.CIR-19-0568
doi:

Substances chimiques

B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

844-850

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Marie-Claire Wagle (MC)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. zineb.mounir@mail.mcgill.ca mariewagle@gmail.com.
ORCID: 0000-0002-8657-1538

Joseph Castillo (J)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Shrividhya Srinivasan (S)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Thomas Holcomb (T)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Kobe C Yuen (KC)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Edward E Kadel (EE)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
ORCID: 0000-0003-3030-6628

Sanjeev Mariathasan (S)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Daniel L Halligan (DL)

Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
ORCID: 0000-0003-4726-6343

Adrian R Carr (AR)

Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.

Max Bylesjo (M)

Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.

Paul R McAdam (PR)

Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.

Sarah Lynagh (S)

Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.

Koen M Marien (KM)

HistoGeneX, Antwerp, Belgium.
ORCID: 0000-0001-7212-7682

Mark Kockx (M)

HistoGeneX, Antwerp, Belgium.

Yannick Waumans (Y)

HistoGeneX, Antwerp, Belgium.
ORCID: 0000-0002-7179-6822

Shih-Min A Huang (SA)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Mark R Lackner (MR)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.

Zineb Mounir (Z)

Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. zineb.mounir@mail.mcgill.ca mariewagle@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes TIL › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Diagnostic › Pronostic › Grading des tumeurs › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Phénomènes génétiques › Recombinaison génétique › Fusion de gènes › Fusion oncogène › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumor Fusion Burden as a Hallmark of Immune...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Analyse de séquence d'ARN › RNA-Seq › Tumor Fusion Burden as a Hallmark of Immune...